Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer
(Thomson Reuters ONE) -
UTRECHT, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced the appointment of L. Andres
Sirulnik, MD, PhD, to the position of Chief Medical Officer, where he will be
responsible for leading the Company's global clinical development strategy and
clinical operations. Dr. Sirulnik will report to Ton Logtenberg, PhD, Chief
Executive Officer of Merus, and will be based in the Company's US Cambridge
office.
"Andres possesses an in-depth knowledge of immuno-oncology with more than 20
years of clinical and industry experience, and we look forward to his expertise
as we advance the development of our novel portfolio of Biclonics®," said Ton
Logtenberg, PhD, Chief Executive Officer of Merus. "Andres has an extensive
background in oncology drug development, medical affairs, and regulatory
strategy, and will be a critical asset to the team as we execute on our clinical
vision and strive to bring innovative cancer treatments to patients."
"I am excited to join the passionate team at Merus and lead the Company's
clinical development efforts at this important juncture," commented Dr.
Sirulnik. "Bispecific antibodies attack tumor cells by inhibiting survival
pathways while simultaneously activating the immune system, and this
multifaceted approach holds great promise across a broad range of cancer types,
both as monotherapy as well as in combination with other treatments. Together
with the leadership team, I look forward to making a contribution to its
clinical development efforts."
Prior to joining Merus, Dr. Sirulnik held numerous positions of increasing
responsibility at Novartis, most recently serving as Vice President and Senior
Global Clinical Program Head where he oversaw the clinical strategy for the
immune-oncology portfolio. Prior, Dr. Sirulnik served as attending physician at
the Dana-Farber Cancer Institute and Brigham and Women's Hospital, and was a
fellow in Hematology/Oncology at Mount Sinai Health System in New York City.
Dr. Sirulnik completed his medical residency at North Shore-Long Island Jewish
(LIJ) Health System and conducted post doctorate work at Columbia University in
New York City. He received his PhD in Medicine and Molecular Biology from King's
College, University of Cambridge in England and his MD from Universidad de
Buenos Aires in Argentina.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such as
long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe
as a potential treatment for HER2-expressing solid tumors. Merus' second
bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2
clinical trial in patients with acute myeloid leukemia. The Company also has a
pipeline of proprietary bispecific antibody candidates in preclinical
development, including MCLA-158, which is designed to bind to cancer stem cells
and is being developed as a potential treatment for colorectal cancer and other
solid tumors, and Biclonics® designed to bind to various combinations of
immunomodulatory molecules, including PD-1 and PD-L1.
Contacts:
Merus N.V.
Shelley Margetson - s.margetson(at)merus.nl
+31 (0)30 253 8800
Argot Partners
Kimberly Minarovich - kimberly(at)argotpartners.com
1-212-600-1902
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 502963
Anzahl Zeichen: 4672
contact information:
Town:
Utrecht
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Merus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
